BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21082951)

  • 1. Hepatosplenic T-cell lymphoma and TNF-α inhibitors.
    Pozadzides JV; Pro B
    Expert Rev Hematol; 2009 Dec; 2(6):611-4. PubMed ID: 21082951
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma.
    Mansour MR; Dogan A; Morris EC; Khwaja A; Linch DC; Mackinnon S; Peggs KS
    Bone Marrow Transplant; 2005 May; 35(9):931-4. PubMed ID: 15778731
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
    Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
    Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
    Thai A; Prindiville T
    J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
    Rosh JR; Oliva-Hemker M
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):165-7. PubMed ID: 17255825
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatosplenic gamma-delta T-cell lymphoma.
    Ferreri AJ; Govi S; Pileri SA
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):283-92. PubMed ID: 22047938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
    Ochenrider MG; Patterson DJ; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):144-8. PubMed ID: 20371449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful allogeneic bone marrow transplantation for hepatosplenic gammadelta T cell lymphoma.
    Ooi J; Iseki T; Adachi D; Yamashita T; Tomonari A; Tojo A; Tani K; Asano S
    Haematologica; 2001 Oct; 86(10):E25. PubMed ID: 11602432
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing hepatosplenic gammadelta T-cell leukemia-lymphoma in children.
    Lo Nigro L; Munda S; Poli A; Licciardello M; D'Amico S; Di Cataldo A
    Pediatr Blood Cancer; 2007 Oct; 49(5):763. PubMed ID: 17120239
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases.
    Lu CL; Tang Y; Yang QP; Wang M; Zhao S; Bi CF; Jiang NG; Zhang WY; Liu JP; Xu X; Liu WP
    Hum Pathol; 2011 Dec; 42(12):1965-78. PubMed ID: 21683978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma.
    He S; Roberts A; Ritchie D; Grigg A
    Leuk Lymphoma; 2007 Jul; 48(7):1448-50. PubMed ID: 17613781
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.
    Yabe M; Medeiros LJ; Daneshbod Y; Davanlou M; Bueso-Ramos CE; Moran EJ; Young KH; Miranda RN
    Ann Diagn Pathol; 2017 Feb; 26():16-22. PubMed ID: 28038706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of effective use of alemtuzumab in a male patient with T-cell lymphoma].
    Sokolov AH; Parovichnikova EN; Isaev VG; Ustinova EN; Shavlokhov VS; Atopkov VA; Model SV; Tsyba NN; Kaplanskaia IB; Kliasova GA; Aleksanian MZh; Vishnevskaia ES; Togonidze DK; Mirzoian EE; Savchenko VG
    Ter Arkh; 2004; 76(12):73-5. PubMed ID: 15724932
    [No Abstract]   [Full Text] [Related]  

  • 14. Gastroenterology: Hepatosplenic T cell lymphoma associated with schistosomiasis.
    Azevedo P; Pedrosa MS; Resende V
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1333. PubMed ID: 26211690
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
    Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
    Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
    Drini M; Prichard PJ; Brown GJ; Macrae FA
    Med J Aust; 2008 Oct; 189(8):464-5. PubMed ID: 18928444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma.
    Rashidi A; Cashen AF
    Blood Cancer J; 2015 Jun; 5(6):e318. PubMed ID: 26047388
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma.
    Sumi M; Takeda W; Kaiume H; Kirihara T; Kurihara T; Sato K; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Kobayashi H
    Leuk Lymphoma; 2015 Apr; 56(4):1140-2. PubMed ID: 25065703
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatosplenic T cell lymphoma in inflammatory bowel disease.
    Shale M; Kanfer E; Panaccione R; Ghosh S
    Gut; 2008 Dec; 57(12):1639-41. PubMed ID: 18667489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.